[Editorial] Age-related macular degeneration: treatment at what cost?
An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration (AMD). A Seminar by Paul Mitchell and colleagues in today’s Lancet describes the latest developments in this devastating condition. The first symptoms of visual distortion or scotoma in one eye might indicate early-phase disease. Later stage AMD is classed as either wet, characterised by choroidal neovascularisation, or dry, characterised by atrophy. Beyond slowing disease progression with micronutrient supplementation, atrophic AMD has no treatment.